International Society for Pharmacoepidemiology

Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation

Retrieved on:

Wednesday, August 23, 2023

Doctor of Pharmacy, Drug development, Syndication, Policy, Research, Doctor of Philosophy, Forecasting, Customer insight, SSI, HIV disease progression rates, RWE, Health, Health information management, International Society for Pharmacoepidemiology, International Society, ICPE, Safety, Medical imaging, Management

DURHAM, N.C., Aug. 23, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced today the launch of its pioneering suite of advanced analytical solutions. Designed to identify unmet needs and answer critical strategic questions along a pharmaceutical product's life cycle, the novel solutions visualize and analyze data using innovative epidemiological methods and sound statistical principles.

Key Points:

Recognizing the demand for enhanced RWE capabilities, Target RWE has developed its own proprietary analytical platform to power its Syndicated Science Insights (SSI) solutions.
"Target RWE believes in empowering healthcare stakeholders with advanced tools they need to thrive in an ever-changing environment.
There are different offerings within the suite of SSI solutions, including Market Insights, Community Insights, and Customized Insights.
In addition, the company will be presenting new innovative research and a pre-conference education session on approaches to pragmatic randomized clinical trials.

Target RWE Strengthens Industry Leadership Position with Novel Real World Evidence Approaches Presented at ICPE 2023

Retrieved on:

Tuesday, August 22, 2023

Target RWE will also be presenting at a pre-conference educational session surrounding new research approaches to pragmatic randomized clinical trials.

Key Points:

Target RWE will also be presenting at a pre-conference educational session surrounding new research approaches to pragmatic randomized clinical trials.
Participants will gain insight into current and recent pragmatic trial case examples with regard to their ‎methods, implementation, operational challenges, and intended use as real world evidence.
Characterizing the Distribution of Multiple Negative Control Outcome Risk Differences, Saturday, August 26, 2023, 11:30am-1:00pm.David Pritchard, PhD, Director, Data Management and Statistics, Target RWE.
Target RWE is officially launching a suite of innovative analytical solutions called Syndicated Science™ Insights (SSI) at ICPE 2023.

Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting

Retrieved on:

Monday, May 8, 2023

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.

Key Points:

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.
The Summit is co-located with and being held immediately prior to the Society’s annual international conference, ISPOR 2023 .
The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy.
ISPOR is a leading professional society for health economics and outcomes research.

Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program Showing No Adverse Safety Signals Among US Veterans Health Administration Patients

Retrieved on:

Tuesday, August 30, 2022

BOSTON, Aug. 30, 2022 /PRNewswire/ -- During the International Society of Pharmacoepidemiology's annual meeting, researchers from Analysis Group (a global leader in health care consulting), the Veterans Health Administration (VHA), and Pfizer presented interim data from 1,448,043 US veterans who were among the first to receive the Pfizer-BioNTech COVID-19 vaccine, between December 11, 2020, and September 24, 2021. In this interim analysis, no adverse safety signals were found among the study population, who overwhelmingly completed the primary series of two doses (96%). With study completion planned for December 2023, the safety of the vaccine will continue to be evaluated by study investigators.

Key Points:

In this interim analysis, no adverse safety signals were found among the study population, who overwhelmingly completed the primary series of two doses (96%).
With study completion planned for December 2023, the safety of the vaccine will continue to be evaluated by study investigators.
Analysis Group researchers designed the study protocol and collaborated with the VHA to identify near real-time safety signals among vaccinated individuals over the course of 30 months.
Forty-six pre-specified safety events of interest were included in the vaccine safety surveillance program, including cerebrovascular non-hemorrhagic stroke, acute myocardial infarction, chilblain-like lesions, anaphylaxis, and acute kidney injury.

New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)

Retrieved on:

Thursday, August 25, 2022

DURHAM, N.C., Aug. 25, 2022 /PRNewswire/ -- Target RWE will present a range of methodological and applied research at the 2022 International Society for Pharmacoepidemiology's annual conference (ICPE) in Copenhagen.

Key Points:

DURHAM, N.C., Aug. 25, 2022 /PRNewswire/ -- Target RWE will present a range of methodological and applied research at the 2022 International Society for Pharmacoepidemiology's annual conference (ICPE) in Copenhagen.
"The work being presented at ICPE by my colleagues at Target RWE highlights the methodological rigor and creativity that characterize our team," said M. Alan Brookhart, PhD, Chief Scientific Officer, Target RWE.
As a sponsor of ICPE 2022, Target RWE additionally unveiled its new brand and Syndicated Science analytical solution at the event.
Target RWE PHRs provide access to rigorously developed and regularly updated RWE in specific clinical areas.

Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022

Retrieved on:

Tuesday, August 23, 2022

"As Target RWE prioritizes the advancement of real world evidence for the global community, we are proud to unveil our newly aligned brand which reflects a best-in-class RWE solution that is unique to the industry," said Derek Evans, Chief Executive Officer, Target RWE.

Key Points:

"As Target RWE prioritizes the advancement of real world evidence for the global community, we are proud to unveil our newly aligned brand which reflects a best-in-class RWE solution that is unique to the industry," said Derek Evans, Chief Executive Officer, Target RWE.
During the conference, Target RWE will introduce its newest web-deployed, interactive Syndicated Science analytical solution Population Health Research Applications (PHRs).
Learn more about Target RWE: www.targetrwe.com
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare.

DGAP-News: Temedica wins further renowned industry representatives for expert advisory board

Retrieved on:

Tuesday, April 26, 2022

MSD, Sentinel, Drug development, CEO, NIH, Board of directors, World government, US Foods, Industry, Principal investigator, Research, Federalisation of the European Union, Food, Merck Group, European Federation of Pharmaceutical Industries and Associations, Federal Joint Committee (Germany), Patient, Merck, Hospital, Electronics, EFPIA, Health, BioNTech, Method, Hewlett-Packard, Epidemiology, International Society for Pharmacoepidemiology, Division, Pharmaceutical Association of Mauritius, Advisory board, International Society, Veterinary medicine, Cone Health Women's Hospital, Plasma protein binding, National Executive Board of the Boy Scouts of America, HIV disease progression rates, FDA, Harvard Medical School, Merck & Co., Darmstadt, University of Hanover, Association, Medical device, Pharmaceutical industry, Medicine, Aetion, Pharmacoepidemiology

Dr. Rainer Hess, Prof. Dr. Norbert Klusen and Rudi Lamprecht will continue to serve on the expert advisory board ( https://temedica.com/en/about-us/#experts ).

Key Points:

Dr. Rainer Hess, Prof. Dr. Norbert Klusen and Rudi Lamprecht will continue to serve on the expert advisory board ( https://temedica.com/en/about-us/#experts ).
Gloria Seibert, Founder & Chief Executive Officer at Temedica, said:
"We are proud to win further internationally renowned personalities for our expert advisory board.
With Dr. Seimetz, Dr. Oschmann, and Prof. Dr. Dr. Schneeweiss, we expand our advisory board with high-caliber and broad expertise.
I am delighted to join Temedica as part of their expert advisory board and to help harness the enormous potential of real-world evidence for the entire industry."

ISPE Convenes Regulators and Industry to Discuss Challenges & Solutions for Quality Risk Management

Retrieved on:

Thursday, May 6, 2021

Health sciences, Life sciences, Health care, ISPE, Pharmacy, Center for Drug Evaluation and Research, Food and Drug Administration, Pharmaceutical industry, Good practice, International Society for Pharmacoepidemiology

b'NORTH BETHESDA, Md., May 6, 2021 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) will convene regulators and industry leaders from around the world at the 2021 ISPE Global Pharmaceutical Regulatory Summit on 16 June and at the 2021 ISPE Asia Pacific Pharmaceutical Manufacturing Conference on 1718 June 2021.

Key Points:

b'NORTH BETHESDA, Md., May 6, 2021 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) will convene regulators and industry leaders from around the world at the 2021 ISPE Global Pharmaceutical Regulatory Summit on 16 June and at the 2021 ISPE Asia Pacific Pharmaceutical Manufacturing Conference on 1718 June 2021.
"\n"Collaboration and communication are a crucial element in mitigating the impact of COVID-19 on pharmaceutical operations, "said Carmelo Rosa, PsyD, Director, Division of Drug Quality I, FDA/CDER/OC/OMQ, and Conference Co-Chair.
The 18,000 Members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.
Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA.

ISPE Gathers Global Health Authorities to Discuss Remote/Distant Assessments, Audits, and Regulatory Guidance

Retrieved on:

Tuesday, April 13, 2021

Health sciences, Pharmaceutical sciences, ISPE, Pharmaceutical industry, Health care, Good practice, Pharmaceuticals policy, International Society for Pharmacoepidemiology, Good automated manufacturing practice

b'NORTH BETHESDA, Md., April 13, 2021 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) will convene regulators, auditors, remote auditors, and inspectors representing 11 regulatory agencies from around the world at the 2021 ISPE Global Pharmaceutical Regulatory Summit for critical discussions on onsite inspection challenges due to COVID-19.

Key Points:

b'NORTH BETHESDA, Md., April 13, 2021 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) will convene regulators, auditors, remote auditors, and inspectors representing 11 regulatory agencies from around the world at the 2021 ISPE Global Pharmaceutical Regulatory Summit for critical discussions on onsite inspection challenges due to COVID-19.
"This event is another means for ISPE to provide a platform to enable these transparent conversations in the industry that includes representatives and perspectives from worldwide regulatory authorities.
The 18,000 Members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.
Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA.

2020-2021 Board of Directors Installed at 2020 ISPE Annual Meeting & Expo

Retrieved on:

Friday, November 6, 2020

ISPE, Pharmaceuticals policy, Good practice, International Society for Pharmacoepidemiology, Pharmaceutical industry, Good automated manufacturing practice

BETHESDA, Md., Nov. 6, 2020 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) installed its 20202021 International Board of Directors during the virtual 2020 ISPE Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.

Key Points:

BETHESDA, Md., Nov. 6, 2020 /PRNewswire-PRWeb/ --The International Society for Pharmaceutical Engineering (ISPE) installed its 20202021 International Board of Directors during the virtual 2020 ISPE Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.
The Board is responsible for the governance and strategic direction of the Society.
The International Society for Pharmaceutical Engineering (ISPE) is a not-for-profit association serving its Members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.
Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA.